READ: Featured Drug Insights: April 2025 - Prime Therapeutics
READ: Featured Drug Insights: April 2025
Your source for all Prime Therapeutics' April 2025 Drug Insights publications.
Prime Therapeutics (Prime) provides you with regular updates on the drug pipeline as well as next-generation clinical information and hot topics. The following Drug Insights publications for April 2025 will keep you informed on what’s trending now.
Released April 29, 2025
A review of newly approved specialty drugs, recent drug launches and new indications in the last month, this edition includes diazoxide choline (Vykat XR), gepotidacin (Blujepa), finasteride/tadalafil capsule (Entadfi) and more.
An overview of clinical insights’ trending topics and timely drug information highlights, including a U.S. Government Accountability Office report on drug shortages and more.
Released April 25, 2025
Dive into clinical insights and competitive intelligence on anticipated drugs in development, so you are well-sourced on the drug pipeline.
Released April 24, 2025
Prime provides a quarterly drug pipeline report of anticipated new drugs, deep dives and indications for the following pipelines: traditional, specialty drugs, biosimilars, and gene and cell therapy.
Released April 15, 2025
Providing a clinical deep dive into a select high cost drug in the pipeline, this month’s profile features Pegzilarginase Intravenous (IV), Subcutaneous (SC) | Immedica Metabolic and more.
Released April 14, 2025
FDA Decisions Expected for May 2025
A breakdown of FDA decisions expected of new drugs expected to hit the market, this edition covers ustekinumab biosimilar (BAT2206), pegzilarginase and more.
Featuring commentary by Simone Ndujiuba, PharmD, BCOP on developments in the oncology space, this installment features approved innovative therapy and the continued unmet needs of pancreatic cancer.
Released April 2, 2025
A monthly report of the most notable drugs that may significantly affect the populations we serve. Drug highlights this month are prademagene zamikeracel / (Abeona), brensocatib / Insmed, rebisufligene etisparvovec / (Ultragenyx) and more.
Looking for previous 2025 drug insights publications?
Simply click on the month to access past editions of our drug insights.
All brand names are property of their respective owners.